|
市場調查報告書
白血病：新產品・組合計畫・授權分析
Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
|
白血病：新產品・組合計畫・授權分析 是由出版商BioSeeker Group AB在2009年04月所出版的。
這份英文市場調查報告書價格從美金2828起跳。
本報告書內容包括：175種白血病治療藥開發策略最新動向、新的商業機會、授權及收購機會等。內容綱要摘記如下：
第1章 實施概要
第2章 關於癌症
第3章 方法
第4章 目次
第5章 介紹
第6章 利用白血病產品線藥的藥物標的標竿學習
- 癌症基因計畫及白血病標的
- 白血病結構基礎的藥物計畫受到與生物學標的相關可到手的結構資料刺激
- 特定白血病標的之標的間的相互作用
- 藥物標的相互作用組
- 蛋白發現水準
- 路徑分析
第7章 新產品的抬頭
- 預定上市的登記前藥物
- 第3期醫療實驗
- 第2期醫療實驗
- 第1期醫療實驗
- 前醫療實驗
- 所有的標的開發介紹
第8章 作業中的化合物策略：化合物別競爭標竿學習
- 小分子
- 縮氨酸・蛋白質
- 抗體・類抗體結構
- 核酸治療
- 基因治療
- 投藥及奈米科技
- 根據次細胞局部化的化合物策略
第9章 組合計畫：醫療實驗負責醫師的標竿學習
第10章 免責事項
第11章 藥物索引
第12章 企業索引
圖表
Abstract
This report includes defined and up to date development strategies for 175
leukemia drugs (<250 projects) within the portfolio of 126 investigators,
from Preclinical to Marketed. Leukemia drugs are further dived into the
sub-indications of ALL, AML, CLL, CML, HCL and MCL. The report is written for
you to understand and assess the impact of competitor entry and corresponding
changes to development strategies for your own portfolio products. It serves
as an external commercial advocate for pharmaceutical companies' portfolio
planning and new product planning by:
- Providing competitive input to the R&D organization to guide development
of early product ideas and ensure efforts are aligned with business objectives
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing commercial analytic support for due diligence on in-licensing
and acquisition opportunities
This report will also be an important part of creating and implementing a
market development plan for any leukemia drugs to ensure that the optimal
market conditions exist by the time the product is commercialized.
BioSeeker' s leukemia pipeline evaluation of development options, competitive
landscape and positioning is derived through extensive pipeline benchmarking
analysis, including:
Single Drug Target Analysis of 136 Drug Targets
- Highlighting twelve themes about the drug target (i.e. Drugs and
investigators sharing a particular target, Types of compounds aimed at a
specific target, Protein-protein interactions of a specific target with other
known leukemia drug targets, Pathway involvement of a drug target, Presence of
structural and protein expression data of a target etc.)
- Supportive chapters on selected drug themes above
Competitive Landscape Analysis based on 115 Identified Drug Target Combinations
- Identifies New and Unique leukemia drugs by developmental stage
- Head-to-head targeting competition
- Targeting competition by at least 50% bi-directional drug target
combination match
- Clinical validation and progress on all identified drug target combinations
Competitive Landscape Analysis based on Compound Strategies at Work
- Identifies New and Unique leukemia drugs based on six different compound
strategies (Small molecules, Peptide/Protein, Antibody, Nucleic acid
therapies, Gene therapy and Re-formulation drugs)
- Head-to-head targeting competition
- Targeting competition by at least 50% bi-directional drug target
combination match
Competitive Benchmarking of Leukemia Pipeline by 126 Investigators
- Competitive Fall-out table for each of the included investigators'
leukemia pipeline, overlaid with head-to-head targeting competitors' drugs
- Competitive summary profile for each one of the 175 included leukemia drugs
Table of Contents
1. Executive Summary
2. About Cancer Highlights
3. Methodologies
4. Table of Contents
- 4.1 List of Figures
- 4.2 List of Tables
5. Introduction
6. Single Drug Target Benchmarking from the Leukemia Pipeline
- 6.1.1 Carboxy-Lyase Activity Targets
- 6.1.2 Catalytic Activity Targets
- 6.1.3 Cell Adhesion Molecule Activity Targets
- 6.1.4 Chaperone Activity Targets
- 6.1.5 Cysteine-Type Peptidase Activity Targets_
- 6.1.6 Cytokine Activity Targets
- 6.1.7 Deaminase Activity Targets
- 6.1.8 DNA Repair Protein Targets
- 6.1.9 DNA Topoisomerase Activity Targets
- 6.1.10 DNA-Directed DNA Polymerase Activity Targets
- 6.1.11 DNA-Methyltransferase Activity Targets
- 6.1.12 G-Protein Coupled Receptor Activity Targets
- 6.1.13 Growth Factor Activity Targets
- 6.1.14 Hydrolase Activity Targets
- 6.1.15 Kinase Activity Targets
- 6.1.16 Kinase Regulator Activity Targets
- 6.1.17 Ligand-Dependent Nuclear Receptor Activity Targets
- 6.1.18 Ligase Activity Targets
- 6.1.19 Lipid Kinase Activity Targets
- 6.1.20 MHC Class I Receptor Activity Targets
- 6.1.21 Molecular Function Unknown Targets
- 6.1.22 Motor Activity Targets
- 6.1.23 Oxidoreductase activity Targets
- 6.1.24 Phosphoric diester hydrolase activity Targets
- 6.1.25 Phosphorylase activity Targets
- 6.1.26 Protein Binding Targets
- 6.1.27 Protein serine/threonine kinase activity Targets
- 6.1.28 Protein tyrosine phosphatase activity Targets
- 6.1.29 Protein-tyrosine kinase activity Targets
- 6.1.30 Receptor Activity Targets
- 6.1.31 Receptor Signaling Complex Scaffold Activity Targets
- 6.1.32 RNA Binding Targets
- 6.1.33 RNA-Directed DNA Polymerase Activity Targets
- 6.1.34 Serine-Type Peptidase Activity Targets
- 6.1.35 Structural Constituent Of Cytoskeleton Targets
- 6.1.36 Superoxide dismutase activity Targets
- 6.1.37 T Cell Receptor Activity Targets
- 6.1.38 Transcription Factor Activity Targets
- 6.1.39 Transcription Regulator Activity Targets
- 6.1.40 Transferase Activity Targets
- 6.1.41 Translation Regulator Activity Targets
- 6.1.42 Transmembrane receptor activity Targets_
- 6.1.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
- 6.1.44 Transporter activity Targets
- 6.1.45 Other Targets
- 6.2 The Cancer Genome Project and Leukemia Targets
- 6.2.1 Leukemia Targets Present in the Cancer Gene Census and in the
Catalogue of Somatic Mutations in Cancer
- 6.3 Structure-based Drug Design in Leukemia is Stimulated by Available
Structure Data on Biological Targets
- 6.4 Target-Target Interactions among Identified Leukemia Targets
- 6.5 The Drug-Target Interactome
- 6.6 Protein Expression Levels of Identified Drug Targets of Leukemia
Drugs
- 6.7 Pathway Analysis of Leukemia Drug Targets
7. The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Combinations Identified in the Leukemia Pipeline?
- 7.1 Pre-Registration to being Marketed: New and Unique Drug Target
Combinations of the Leukemia Pipeline
- 7.2 Phase III Clinical Development: New and Unique Drug Target
Combinations of the Leukemia Pipeline
- 7.3 Phase II Clinical Development: New and Unique Drug Target
Combinations of the Leukemia Pipeline
- 7.4 Phase I Clinical Development: New and Unique Drug Target
Combinations of the Leukemia Pipeline
- 7.5 Preclinical Development: New and Unique Drug Target Combinations of
the Leukemia Pipeline
- 7.6 Development Profiles of All Leukemia Drug Target Combinations
Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound
- 8.1 Small Molecules
- 8.1.1 Background
- 8.1.2 Targets in Leukemia
- 8.2 Peptide/Protein Drugs
- 8.2.1 Background
- 8.2.2 Targets in Leukemia
- 8.3 Antibodies and Antibody-like Structures
- 8.3.1 Background
- 8.3.2 Targets in Leukemia
- 8.4 Nucleic Acid Therapies
- 8.4.1 Background
- 8.4.2 Targets in Leukemia
- 8.5 Gene Therapy
- 8.5.1 Background
- 8.5.2 Targets in Leukemia
- 8.6 Drug Delivery and Nanotechnology
- 8.6.1 Background
- 8.6.2 Targets in Leukemia
- 8.7 Compound Strategies based on Sub-Cellular Localization of Leukemia
Drug Targets
9. Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator
- 9.1 4SC
- 9.2 Abbott
- 9.3 Abiogen
- 9.4 Actinium Pharmaceuticals
- 9.5 AEgera
- 9.6 Aeterna Zentaris
- 9.7 Agennix
- 9.8 Alexion
- 9.9 Alfa Wassermann
- 9.10 Ambit Biosciences
- 9.11 Amgen
- 9.12 Antigenics
- 9.13 Antisoma
- 9.14 Ariad
- 9.15 Arno Therapeutics
- 9.16 Array BioPharma
- 9.17 Asahi Kasei Pharma
- 9.18 Ascenta Therapeutics
- 9.19 Astellas
- 9.20 Astex Therapeutics
- 9.21 AstraZeneca
- 9.22 Attenuon
- 9.23 Bayer
- 9.24 BioCryst Pharmaceuticals
- 9.25 Biogen Idec
- 9.26 Bioton
- 9.27 Boehringer Ingelheim
- 9.28 Bristol-Myers Squibb
- 9.29 BTG
- 9.30 Calistoga Pharmaceuticals
- 9.31 Callisto Pharmaceuticals
- 9.32 Celator Pharmaceuticals
- 9.33 Cell Genesys
- 9.34 Cell Therapeutics
- 9.35 Cephalon
- 9.36 CJ Corp
- 9.37 Clavis Pharma
- 9.38 Curacyte
- 9.39 Cyclacel
- 9.40 Cylene Pharmaceuticals
- 9.41 CytImmune Sciences
- 9.42 Cytokinetics
- 9.43 Daiichi Sankyo
- 9.44 Dainippon Sumitomo Pharma
- 9.45 Dara Biosciences
- 9.46 Deciphera Pharmaceuticals
- 9.47 Dong-A
- 9.48 Eleos
- 9.49 Eli Lilly
- 9.50 Enzon
- 9.51 EpiCept
- 9.52 Exelixis
- 9.53 ExonHit Therapeutics
- 9.54 Gemin X Pharmaceuticals
- 9.55 Genentech
- 9.56 Genmab
- 9.57 Genta
- 9.58 Genzyme
- 9.59 Geron
- 9.60 GlaxoSmithKline
- 9.61 Gloucester Pharmaceuticals
- 9.62 GlycoGenesys
- 9.63 Hayashibara
- 9.64 Hoffmann-La Roche
- 9.65 ImClone Systems
- 9.66 Immunomedics
- 9.67 Innate Pharma
- 9.68 Innovive
- 9.69 Isis Pharmaceuticals
- 9.70 Italfarmaco
- 9.71 Johnson & Johnson
- 9.72 Kanisa
- 9.73 Kyowa Hakko Kirin
- 9.74 LG Life Sciences
- 9.75 Lorus Therapeutics
- 9.76 MAT Biopharma
- 9.77 MaxCyte
- 9.78 Meda
- 9.79 Medarex
- 9.80 MethylGene
- 9.81 Micromet
- 9.82 MorphoSys
- 9.83 NanoMed Pharmaceuticals
- 9.84 Nerviano Medical Sciences
- 9.85 National Institute of Health (USA)
- 9.86 Nippon Shinyaku
- 9.87 Novartis
- 9.88 Novogen
- 9.89 PDL BioPharma
- 9.90 Peplin
- 9.91 Pfizer
- 9.92 Pharmacyclics
- 9.93 PharmaMar
- 9.94 PIERIS Proteolab
- 9.95 Rigel
- 9.96 Sanofi-Aventis
- 9.97 Santaris Pharma
- 9.98 SBIO
- 9.99 Schering-Plough
- 9.100 SciGen
- 9.101 Seattle Genetics
- 9.102 Sepal Pharma
- 9.103 Servier
- 9.104 Shantha Biotechnics
- 9.105 Sidus
- 9.106 Spirogen
- 9.107 Stemline Therapeutics
- 9.108 SuperGen
- 9.109 Supratek Pharma
- 9.110 Swedish Orphan
- 9.111 SymBio Pharmaceuticals
- 9.112 Takeda
- 9.113 Teva
- 9.114 TopoTarget
- 9.115 Trion Pharma
- 9.116 Trubion
- 9.117 Vertex Pharmaceuticals
- 9.118 Vion Pharmaceuticals
- 9.119 VioQuest
- 9.120 Wyeth
- 9.121 Yamasa Corporation
- 9.122 Zenyaku Kogyo
- 9.123 ZymoGenetics
- 9.124 Non-Industrial Sources
10. Disclaimer
11. Drug Index
12. Company Index
4.1 List of Figures
- Figure 1: Overall Breakdown of Included Leukemia Pipeline by
Sub-indication and Stage of Development
- Figure 2: Visualization of Target-Target Interactions Among Leukemia Drug
Targets
- Figure 3: The Drug-Protein Interactome of Leukemia Drugs - The Main
Cluster
- Figure 4: The Drug-Protein Interactome of Leukemia Drugs - Smaller
Clusters
- Figure 5: Head-to-Head Targeting Interactome of Leukemia Drugs
- Figure 6: Distribution of Compound Types among Leukemia Drugs
- Figure 7: Primary Sub-cellular Localization of Drug Targets
4.2 List of Tables
- Table 1: Overview of Drug Target Profile Themes
- Table 2: Drug Targets of Leukemia Drugs Present in the Catalogue of
Somatic Mutations in Cancer and in the Cancer Gene Census
- Table 3: Identity of Leukemia Drug Targets with Available Biological
Structures
- Table 4: Number of Target-Target Interactions among Leukemia Drug Targets
- Table 5: Drug-Protein Interactome Clusters
- Table 6: Leukemia Drug Targets with Available Protein Expression Profiles
- Table 7: Pathway Summary
- Table 8: Drug Targets without any Identified Assigned Pathways
- Table 9: Pathway Profile According to BioCarta of Leukemia Drug Targets
- Table 10: Pathway Profile According to KEGG of Leukemia Drug Targets
- Table 11: Pathway Profile According to NetPath of Leukemia Drug Targets
- Table 12: Number of Drug Target Combinations by the Highest Developmental
Stage and Uniqueness
- Table 13: Top 5 Competitive Leukemia Targets
- Table 14: New and Unique Leukemia Targets in Pre-Registration to Marketed
- Table 15: New and Unique Leukemia Targets in Phase III Clinical Development
- Table 16: New and Unique Leukemia Targets in Phase II Clinical Development
- Table 17: New and Unique Leukemia Targets in Phase I Clinical Development
- Table 18: New and Unique Leukemia Targets in Preclinical Development
- Table 19: The Progression, Maturity and Competitive Comparison of Leukemia
Drug Target Combinations in Development
- Table 20: Number of Leukemia Drug Target Mixes Reported by Compound
Strategy
- Table 21: Number of Head-to-head Competing Small Molecule Drugs for the
Treatment of Leukemia by Drug Target
- Table 22: Drug Targets of Small Molecule Drugs in Leukemia
- Table 23: The Competition Through Close Mechanistic Approximation Between
Small Molecule Drugs in Leukemia
- Table 24: Drug Targets of Peptide Based Drugs in Leukemia
- Table 25: Drug Targets of Protein Based Drugs in Leukemia
- Table 26: Drug Targets of Antibodies and Antibody-like Drugs in Leukemia
- Table 27: The Competition Through Close Mechanistic Approximation Between
Antibody Drugs in Leukemia
- Table 28: Drug Targets of Nucleic Acid Therapies in Leukemia
- Table 29: Vectors in Gene Therapy
- Table 30: Drug Targets of Gene Therapies in Leukemia
- Table 31: Drug Targets with New Drug Delivery Strategies in Leukemia
- Table 32: Compound Strategies based on Sub-Cellular Localization of
Leukemia Drug Targets
- Table 33: 4SC' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 34: Abbott' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 35: Abiogen' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 36: Actinium Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 37: AEgera' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 38: Aeterna Zentaris' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 39: Agennix' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 40: Alexion' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 41: Alfa Wassermann' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 42: Ambit Biosciences' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 43: Amgen' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 44: Antigenics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 45: Antisoma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 46: Ariad' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 47: Arno Therapeutics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 48: Array BioPharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 49: Asahi Kasei Pharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 50: Ascenta Therapeutics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 51: Astellas' Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 52: Astex Therapeutics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 53: AstraZeneca' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 54: Attenuon' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 55: Bayer' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 56: BioCryst Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 57: Biogen Idec' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 58: Bioton' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 59: Bioton' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 60: Bristol-Myers Squibb' s Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 61: BTG' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 62: Calistoga Pharmaceuticals' Included Leukemia Pipeline
Composition and Competitive Fall-Out
- Table 63: Callisto Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 64: Celator Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 65: Cell Genesys' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 66: Cell Therapeutics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 67: Cephalon' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 68: CJ Corp' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 69: Clavis Pharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 70: Curacyte' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 71: Cyclacel' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 72: Cylene Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 73: CytImmune Sciences' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 74: Cytokinetics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 75: Daiichi Sankyo' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 76: Dainippon Sumitomo Pharma' s Included Leukemia Pipeline
Composition and Competitive Fall-Out
- Table 77: Dara Biosciences' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 78: Deciphera Pharmaceuticals' Included Leukemia Pipeline
Composition and Competitive Fall-Out
- Table 79: Dong-A' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 80: Eleos' Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 81: Eli Lilly' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 82: Enzon' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 83: EpiCept' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 84: Exelixis' Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 85: ExonHit Therapeutics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 86: Gemin X Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 87: Genentech' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 88: Genmab' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 89: Genta' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 90: Genzyme' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 91: Geron' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 92: GlaxoSmithKline' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 93: Gloucester Pharmaceuticals' Included Leukemia Pipeline
Composition and Competitive Fall-Out
- Table 94: GlycoGenesys' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 95: Hayashibara' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 96: Hoffmann-La Roche' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 97: ImClone Systems' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 98: Immunomedics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 99: Innate Pharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 100: Innovive' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 101: Isis Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 102: Italfarmaco' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 103: Johnson & Johnson' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 104: Kanisa' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 105: Kyowa Hakko Kirin' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 106: LG Life Sciences' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 107: Lorus Therapeutics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 108: MAT Biopharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 109: MaxCyte' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 110: Meda' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 111: Medarex' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 112: MethylGene' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 113: Micromet' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 114: MorphoSys' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 115: NanoMed Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 116: Nerviano Medical Sciences' Included Leukemia Pipeline
Composition and Competitive Fall-Out
- Table 117: NIH' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 118: Nippon Shinyaku' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 119: Novartis' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 120: Novogen' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 121: PDL BioPharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 122: Peplin' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 123: Pfizer' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 124: Pharmacyclics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 125: PharmaMar' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 126: PIERIS Proteolab' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 127: Rigel' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 128: Sanofi-Aventis' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 129: Santaris Pharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 130: SBIO' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 131: Schering-Plough' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 132: SciGen' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 133: Seattle Genetics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 134: Sepal Pharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 135: Servier' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 136: Shantha Biotechnics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 137: Sidus' Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 138: Spirogen' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 139: Stemline Therapeutics' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 140: SuperGen' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 141: Supratek Pharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 142: Swedish Orphan' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 143: SymBio Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 144: Takeda' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 145: Teva' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 146: TopoTarget' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 147: Trion Pharma' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 148: Trubion' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 149: Vertex Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 150: Vion Pharmaceuticals' Included Leukemia Pipeline Composition
and Competitive Fall-Out
- Table 151: VioQuest' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 152: Wyeth' s Included Leukemia Pipeline Composition and Competitive
Fall-Out
- Table 153: Yamasa Corporation' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 154: Zenyaku Kogyo' s Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 155: ZymoGenetics' Included Leukemia Pipeline Composition and
Competitive Fall-Out
- Table 156: Non-industrial Sources' Included Leukemia Pipeline Composition
and Competitive Fall-Out
|
